Cardio3 Biosciences to Address American Institutional Investors in January at J.P. Morgan Healthcare Conference

MONT-SAINT-GUIBERT, Belgium, December 15, 2014 /PRNewswire/ --

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation in the 33^rd edition of the annual J.P. Morgan Healthcare Conference which will be held from 12 to 16 January 2015 in San Francisco.

The J.P. Morgan Healthcare conference is the largest and most informative healthcare investment conference. This conference attracts a broad range of US-based analysts and institutional investors.

Cardio3 BioSciences will meet with potential investors and explain to them its on-going development programs and strategic vision for the future.

Patrick Jeanmart, CFO of Cardio3 BioSciences, commented: "2014 was rich in events for our company. We made significant progress in the European Phase III clinical trial of C-Cure® and our strategic development was strengthened by an enlarged collaboration with Mayo Clinic and the acquisition of CorQuest Inc. The J.P. Morgan Healthcare Conference is an excellent opportunity  to present Cardio3 BioSciences'  potential and strategic vision to new investors in view of increasing the visibility and the awareness of our Company towards large institutional investors."

About Cardio3 BioSciences 

Cardio3 BioSciences is a Belgian leading biotechnology company focused on the discovery and development of regenerative and protective therapies for the treatment of unmet medical needs. The company was founded in 2007 and is based in the Walloon region of Belgium. Cardio3 BioSciences leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular Centre Aalst, Belgium.

The Company's lead product candidate C-Cure® is an innovative pharmaceutical product that is being developed for heart failure indication. C-Cure® consists of a patient's own cells that are harvested from the patient's bone marrow and engineered to become new heart muscle. This process is known as Cardiopoiesis.

Cardio3 BioSciences has also developed C-Cath_ez®, the most technologically advanced injection catheter with superior efficiency of delivery of bio therapeutic agents into the myocardium.

Cardio3 BioSciences' shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CARD.

C3BS-CQR-1, C-Cure, C-Cath_ez, Cardio3 BioSciences and the Cardio3 BioSciences and C-Cath_ez logos are trademarks or registered trademarks of Cardio3 BioSciences SA, in Belgium, other countries, or both. Mayo Clinic holds equity in Cardio3 BioSciences as a result of intellectual property licensed to the company. In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of required Phase III studies; additional clinical results validating the use of adult autologous stem cells to treat heart failure; satisfaction of regulatory and other requirements; and actions of regulatory bodies and other governmental authorities.  

For more information, please contact:

Cardio3 BioSciences
http://www.c3bs.com
Christian Homsy, CEO
Julie Grade, Corporate Communications Manager
Tel. : +32-10-39-41-00
[email protected]

For Europe: Citigate Dewe Rogerson
Chris Gardner
Tel : +44-(0)207-638-9571
[email protected]

For the U.S: Rx Communications Group
Eric Goldman
Tel: +1-917-322-2563
[email protected]

To subscribe to Cardio3 BioSciences' newsletter, visit http://www.c3bs.com.

Follow us on Twitter @Cardio3Bio.

@JPMorgan #HealthcareConference

SOURCE Cardio3 BioSciences